Session 3: Vascular, Mucocutaneous, and Bone Complications
Overview
Telomere biology disorders (TBDs) don’t stay confined to one organ. Because short telomeres wear down the cells that divide fastest, the effects show up in tissues that are constantly renewing themselves: skin, nails, the lining of the mouth, the retina in the eye, blood vessels, and bone marrow (which produces blood and immune cells). Session 3 followed the parts of the body we can see most easily to some of the most serious, and least visible, complications of TBDs.
The session opened with a reminder that visible clues in skin, nails, hair, and eyes are often the earliest signs of TBDs, and in places where genetic testing is hard to access, these clues can be the difference between an early diagnosis and a missed one. The talks then went over the fragile blood vessels behind serious eye disease in children, the expanding catalog of skin and mucous membrane findings seen in real patient cohorts, the challenge of treating cancer safely in people whose bodies may respond differently to chemotherapy and radiation, and new data connecting bone fragility to underlying blood vessel dysfunction.
A common theme ran through all five talks: the same short telomere biology that damages skin and mucous membranes may also be quietly damaging blood vessels and bone, often before a formal TBD diagnosis is even made. That is why several speakers called for more systematic, coordinated screening, whether that means an annual skin exam, a bone density scan read the right way, or a multidisciplinary group of specialists reviewing a hard cancer case together. Similar to the previous sessions, viewing TBDs as whole-body conditions, rather than a collection of separate problems, makes that kind of coordinated care possible and essential for TBD patients.
Highlights from Each Talk
Session Introduction/Background: Dr. Alfredo de Jesús Rodríguez Gómez, National Autonomous University of Mexico
Dr. Rodríguez Gómez opened by framing TBDs as truly systemic diseases, which affect the bone marrow, lungs, liver, skin, mouth, nails, eyes, bones, and blood vessels, and driven across the body by short telomeres. He previewed how the session would move from early, visible clues, like changes in skin, nails, and eyes, toward more systemic complications such as cancer and bone fragility. In settings like Mexico, where genetic testing can be hard to access, these visible signs are especially important for catching TBD sooner. His takeaway: because the same underlying biology touches so many organs, a multidisciplinary approach to care matters.
Derm Manifestations and Skin Screening: Dr. Raegan Hunt, Texas Children’s Hospital
Dr. Hunt, a pediatric dermatologist at Texas Children’s Hospital, explained why skin findings matter so much in TBDs: they offer some of the earliest diagnostic clues and skin cancer risk is meaningfully increased in TBD patients, often appearing decades earlier than in the general population (in TBD patients’ 20s and 30s rather than around age 68). The classic triad of skin pigment, nail, and mouth changes is often incomplete, so relying on it alone can miss patients. Her takeaways for families: annual skin exams, monthly self-checks, strict sun protection starting early, and awareness that hand and foot sweating is common and treatable.
Pediatric Retinal Complications: Dr. Marcela Maria Estrada, UC Davis Health
Joining virtually, Dr. Estrada explained that about 40% of people with dyskeratosis congenita develop eye problems, with the most serious findings concentrated in two severe TBD subtypes, Revesz syndrome and Coats plus. Damaged retinal blood vessels can trigger new, fragile vessels that leak and bleed, and left untreated this can progress to retinal detachment and dangerously high eye pressure that sometimes threatens vision entirely. These complications tend to start very young, often around age 1 for Revesz syndrome. Dr. Estrada’s message for families: because young children can struggle to describe symptoms, early, specialized eye care is essential to protect vision and eye health.
An Integrative Approach to Mucocutaneous Findings in TBDs: Insights from a Clinical Case Series. Brenda Avendaño, National Autonomous University of Mexico
Brenda Avendaño, a medical geneticist in Mexico, shared results from a two-year effort documenting skin, nail, mouth, hair, and eye findings in 10 patients with TBDs. Skin changes were the most consistent finding and were present in 8 of 10 patients, while only 3 had the complete classic triad. Her team also identified a possible new finding: small, widened blood vessels on the eyelid were seen in three patients, which may expand what’s recognized as part of the TBD presentation in the skin. Because genetic testing isn’t always accessible where she practices, her group is building a standardized checklist to support earlier suspicion, diagnosis, and follow-up.
From Case to Consensus: A National Tumor Board for DNA Repair and Telomere Biology Disorders. Dr. Richa Sharma, Cleveland Clinic
Dr. Richa Sharma introduced a new National DNA Repair and Telomere Biology Disorders Tumor Board, a monthly meeting where clinicians from multiple institutions discuss especially difficult cancer cases in patients with TBDs. She illustrated the need with real cases in which it was unclear which cancer treatments would be safe, including one where a patient’s cancer team hadn’t known about his underlying TBD diagnosis. These cases underscore a central problem: there is a lack of good evidence for how to safely dose chemotherapy or radiation in TBD patients. The tumor board, run with the CCCTAA consortium, aims to close that gap.
Early Bone Fragility Is Associated with Vascular Abnormalities in Telomere Biology Disorders: Findings from the Multicenter, International INSIGHT Study. Presented by Dr. Myers, on behalf of Dr. Jane Koo, Cincinnati Children’s Hospital Medical Center
This talk shared results from the INSIGHT study, the largest study to date of bone problems in TBDs. Crucial data was integrated from 434 patients across 16 institutions in six countries, and the findings were striking: fragility fractures, low bone density, and avascular necrosis all occur far earlier in TBD patients than in the general population. These sometimes even in childhood and often before a TBD diagnosis was made. Bone problems were also strongly linked to vascular complications like retinal blood vessel disease, which suggests a shared underlying mechanism these systems. The team recommended TBD-specific bone screening, including using Z-scores rather than T-scores, especially for higher-risk patients.
What This Means for the Field
Taken together, these talks make a strong case that TBDs need to be screened for and managed as a whole-body condition. Skin, nail, and eye findings, easy to overlook individually, become powerful diagnostic tools when clinicians know to look for the full range of them, and especially in settings where genetic testing isn’t readily available. Several speakers also pointed to real gaps in knowledge, including how skin findings present differently across different skin tones, how to safely treat cancer in people with TBDs, and why bone fragility and blood vessel disease seem to travel together. That last connection, between blood vessel dysfunction and bone health, may point to a shared underlying mechanism that might involve damage to the cells that line the blood vessels, which researchers are only beginning to understand.
The new National DNA Repair and Telomere Biology Disorders Tumor Board and the international INSIGHT study both reflect a broader shift toward multi-institutional collaboration that pools cases and data across centers and countries in order to answer questions that no single clinic could tackle alone. For patients and families, the practical takeaway is that earlier, more coordinated screening (regular skin exams, appropriate eye care, thoughtfully interpreted bone density scans, and access to multidisciplinary cancer expertise when needed) can catch problems sooner and open the door to better-informed treatment decisions down the road.
